 Gregory Forlenza
Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Infusion Systems | 67 | 2023 | 306 | 14.980 |
Why?
| | Diabetes Mellitus, Type 1 | 89 | 2024 | 3357 | 11.980 |
Why?
| | Pancreas, Artificial | 26 | 2022 | 71 | 9.490 |
Why?
| | Blood Glucose Self-Monitoring | 63 | 2024 | 534 | 9.390 |
Why?
| | Blood Glucose | 81 | 2024 | 1937 | 8.290 |
Why?
| | Insulin | 69 | 2023 | 2153 | 6.870 |
Why?
| | Hypoglycemic Agents | 65 | 2023 | 1031 | 6.600 |
Why?
| | Hypoglycemia | 29 | 2023 | 401 | 6.220 |
Why?
| | Hyperglycemia | 15 | 2023 | 313 | 3.690 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2022 | 535 | 2.380 |
Why?
| | Monitoring, Ambulatory | 5 | 2018 | 84 | 1.870 |
Why?
| | Islets of Langerhans Transplantation | 4 | 2017 | 68 | 1.680 |
Why?
| | Diabetes Mellitus | 7 | 2022 | 939 | 1.610 |
Why?
| | Pancreatectomy | 4 | 2017 | 165 | 1.530 |
Why?
| | Insulin-Secreting Cells | 3 | 2023 | 327 | 1.510 |
Why?
| | Adolescent | 53 | 2024 | 18342 | 1.470 |
Why?
| | Child | 53 | 2024 | 19029 | 1.460 |
Why?
| | Humans | 115 | 2024 | 118066 | 1.320 |
Why?
| | Biomedical Technology | 2 | 2019 | 43 | 1.290 |
Why?
| | Verapamil | 2 | 2023 | 32 | 1.150 |
Why?
| | Pancreatitis, Chronic | 3 | 2017 | 39 | 1.140 |
Why?
| | Patient Education as Topic | 3 | 2021 | 696 | 1.130 |
Why?
| | Young Adult | 31 | 2023 | 10707 | 1.110 |
Why?
| | Telemedicine | 3 | 2022 | 663 | 0.970 |
Why?
| | Technology | 5 | 2023 | 81 | 0.920 |
Why?
| | Calcium Channel Blockers | 1 | 2023 | 114 | 0.880 |
Why?
| | Algorithms | 14 | 2020 | 1520 | 0.860 |
Why?
| | Adult | 42 | 2024 | 31230 | 0.840 |
Why?
| | Male | 47 | 2024 | 57376 | 0.810 |
Why?
| | Lymphoma | 1 | 2023 | 179 | 0.810 |
Why?
| | Female | 44 | 2024 | 61147 | 0.730 |
Why?
| | Patient Dropouts | 1 | 2020 | 66 | 0.700 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 267 | 0.690 |
Why?
| | Child, Preschool | 14 | 2023 | 9442 | 0.690 |
Why?
| | Personal Satisfaction | 1 | 2020 | 183 | 0.670 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2023 | 2159 | 0.650 |
Why?
| | Patient Satisfaction | 2 | 2021 | 609 | 0.640 |
Why?
| | Artificial Intelligence | 1 | 2019 | 137 | 0.620 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 152 | 0.620 |
Why?
| | Glucose | 8 | 2023 | 939 | 0.600 |
Why?
| | Eczema | 1 | 2018 | 85 | 0.600 |
Why?
| | Self-Management | 1 | 2019 | 133 | 0.590 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 160 | 0.590 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.580 |
Why?
| | Machine Learning | 1 | 2020 | 320 | 0.580 |
Why?
| | Diffusion of Innovation | 1 | 2017 | 97 | 0.560 |
Why?
| | Treatment Outcome | 14 | 2023 | 9311 | 0.550 |
Why?
| | Insulin, Regular, Human | 7 | 2023 | 32 | 0.530 |
Why?
| | Endocrine Glands | 1 | 2015 | 16 | 0.520 |
Why?
| | Endocrine System Diseases | 1 | 2015 | 32 | 0.510 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 347 | 0.500 |
Why?
| | Coronavirus Infections | 1 | 2020 | 338 | 0.500 |
Why?
| | Fanconi Anemia | 1 | 2013 | 12 | 0.480 |
Why?
| | Dwarfism | 1 | 2013 | 17 | 0.470 |
Why?
| | Suicide | 1 | 2020 | 496 | 0.470 |
Why?
| | Skin | 1 | 2018 | 658 | 0.460 |
Why?
| | Growth Hormone | 1 | 2013 | 107 | 0.460 |
Why?
| | Diabetic Ketoacidosis | 4 | 2023 | 168 | 0.450 |
Why?
| | Quality of Life | 2 | 2020 | 2360 | 0.440 |
Why?
| | Blindness | 1 | 2012 | 35 | 0.430 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 745 | 0.420 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 449 | 0.420 |
Why?
| | Pandemics | 1 | 2020 | 1339 | 0.410 |
Why?
| | Aged | 17 | 2022 | 19557 | 0.400 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1237 | 0.390 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 218 | 0.380 |
Why?
| | Cross-Over Studies | 5 | 2019 | 448 | 0.380 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 1795 | 0.380 |
Why?
| | Calibration | 3 | 2020 | 134 | 0.380 |
Why?
| | Lingual Frenum | 1 | 2010 | 1 | 0.380 |
Why?
| | Retrospective Studies | 9 | 2024 | 12922 | 0.370 |
Why?
| | Tongue Diseases | 1 | 2010 | 8 | 0.370 |
Why?
| | Epidemics | 1 | 2011 | 70 | 0.370 |
Why?
| | Failure to Thrive | 1 | 2010 | 31 | 0.370 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 522 | 0.360 |
Why?
| | Infant | 6 | 2023 | 8256 | 0.350 |
Why?
| | Double-Blind Method | 4 | 2023 | 1679 | 0.340 |
Why?
| | Models, Biological | 1 | 2016 | 1698 | 0.340 |
Why?
| | Middle Aged | 18 | 2022 | 27434 | 0.330 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4571 | 0.310 |
Why?
| | Skiing | 2 | 2019 | 38 | 0.310 |
Why?
| | Exercise | 7 | 2019 | 1647 | 0.300 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 2 | 2017 | 25 | 0.300 |
Why?
| | Inventions | 2 | 2018 | 17 | 0.300 |
Why?
| | Transplantation, Autologous | 3 | 2017 | 190 | 0.290 |
Why?
| | United States | 10 | 2023 | 12477 | 0.280 |
Why?
| | Postoperative Complications | 2 | 2015 | 2230 | 0.280 |
Why?
| | Overweight | 2 | 2023 | 492 | 0.280 |
Why?
| | Outpatients | 2 | 2021 | 324 | 0.270 |
Why?
| | Endocrinology | 2 | 2018 | 68 | 0.270 |
Why?
| | Risk Factors | 5 | 2020 | 8950 | 0.270 |
Why?
| | Insulin Lispro | 2 | 2022 | 35 | 0.270 |
Why?
| | Insulin Aspart | 2 | 2022 | 26 | 0.270 |
Why?
| | C-Peptide | 2 | 2023 | 139 | 0.270 |
Why?
| | Injections, Subcutaneous | 3 | 2020 | 139 | 0.260 |
Why?
| | Feasibility Studies | 5 | 2018 | 747 | 0.250 |
Why?
| | Body Height | 2 | 2017 | 186 | 0.250 |
Why?
| | Mutation | 1 | 2015 | 3426 | 0.250 |
Why?
| | Insulins | 1 | 2023 | 34 | 0.220 |
Why?
| | Meals | 3 | 2019 | 101 | 0.210 |
Why?
| | Equipment Failure | 3 | 2018 | 114 | 0.210 |
Why?
| | Awareness | 1 | 2023 | 92 | 0.210 |
Why?
| | Pediatrics | 2 | 2020 | 980 | 0.200 |
Why?
| | Automobile Driving | 1 | 2023 | 129 | 0.190 |
Why?
| | Medicaid | 2 | 2022 | 410 | 0.190 |
Why?
| | Infusion Pumps, Implantable | 1 | 2020 | 20 | 0.190 |
Why?
| | Smartphone | 2 | 2019 | 68 | 0.180 |
Why?
| | Medicare | 2 | 2022 | 666 | 0.180 |
Why?
| | Computer Systems | 1 | 2020 | 47 | 0.180 |
Why?
| | Sports | 2 | 2019 | 190 | 0.170 |
Why?
| | Prospective Studies | 5 | 2023 | 6443 | 0.170 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2019 | 64 | 0.170 |
Why?
| | Fatal Outcome | 1 | 2020 | 286 | 0.170 |
Why?
| | Prevalence | 3 | 2023 | 2321 | 0.170 |
Why?
| | Reproducibility of Results | 4 | 2024 | 2855 | 0.170 |
Why?
| | Software | 2 | 2021 | 563 | 0.170 |
Why?
| | Biosensing Techniques | 1 | 2020 | 106 | 0.160 |
Why?
| | Clinical Alarms | 1 | 2017 | 10 | 0.160 |
Why?
| | Night Terrors | 1 | 2017 | 1 | 0.150 |
Why?
| | Insulinoma | 1 | 2017 | 29 | 0.150 |
Why?
| | Device Approval | 1 | 2017 | 21 | 0.150 |
Why?
| | Diet, Diabetic | 1 | 2017 | 34 | 0.150 |
Why?
| | Voluntary Health Agencies | 1 | 2016 | 6 | 0.150 |
Why?
| | Survival Analysis | 1 | 2020 | 1261 | 0.150 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2017 | 29 | 0.150 |
Why?
| | Obesity | 3 | 2023 | 2715 | 0.140 |
Why?
| | Program Evaluation | 1 | 2021 | 834 | 0.140 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 174 | 0.140 |
Why?
| | Pancreaticoduodenectomy | 1 | 2017 | 128 | 0.140 |
Why?
| | Abdominal Pain | 1 | 2017 | 133 | 0.140 |
Why?
| | Statistics as Topic | 1 | 2016 | 304 | 0.130 |
Why?
| | Drug Overdose | 1 | 2020 | 293 | 0.130 |
Why?
| | Hypophosphatasia | 1 | 2015 | 2 | 0.130 |
Why?
| | Age Factors | 3 | 2018 | 2991 | 0.130 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 306 | 0.130 |
Why?
| | Pilot Projects | 2 | 2020 | 1405 | 0.130 |
Why?
| | Consensus | 3 | 2023 | 531 | 0.130 |
Why?
| | Alkaline Phosphatase | 1 | 2015 | 157 | 0.120 |
Why?
| | Autografts | 1 | 2014 | 49 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 276 | 0.120 |
Why?
| | Choristoma | 1 | 2013 | 22 | 0.120 |
Why?
| | Glucose Clamp Technique | 1 | 2014 | 194 | 0.120 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2013 | 30 | 0.120 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 379 | 0.110 |
Why?
| | Postoperative Period | 1 | 2014 | 307 | 0.110 |
Why?
| | Quality Improvement | 1 | 2021 | 962 | 0.110 |
Why?
| | Graft Survival | 1 | 2015 | 496 | 0.110 |
Why?
| | Allografts | 1 | 2013 | 133 | 0.110 |
Why?
| | Patient Compliance | 1 | 2017 | 532 | 0.110 |
Why?
| | Clinical Protocols | 1 | 2014 | 234 | 0.110 |
Why?
| | Pituitary Gland | 1 | 2013 | 163 | 0.110 |
Why?
| | Bionics | 2 | 2022 | 11 | 0.110 |
Why?
| | Body Mass Index | 2 | 2017 | 2074 | 0.110 |
Why?
| | Genetic Testing | 1 | 2015 | 388 | 0.110 |
Why?
| | Pituitary Neoplasms | 1 | 2013 | 165 | 0.110 |
Why?
| | Graft Rejection | 1 | 2015 | 547 | 0.100 |
Why?
| | Adipose Tissue | 1 | 2016 | 595 | 0.100 |
Why?
| | Adolescent Behavior | 1 | 2017 | 480 | 0.100 |
Why?
| | Prognosis | 2 | 2020 | 3421 | 0.100 |
Why?
| | Age of Onset | 1 | 2012 | 463 | 0.100 |
Why?
| | Critical Illness | 1 | 2016 | 662 | 0.090 |
Why?
| | Biomedical Research | 1 | 2016 | 601 | 0.090 |
Why?
| | Activities of Daily Living | 3 | 2017 | 353 | 0.090 |
Why?
| | Global Health | 1 | 2012 | 308 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2017 | 719 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4682 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2016 | 809 | 0.090 |
Why?
| | Biomarkers | 1 | 2020 | 3564 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2012 | 519 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2015 | 3142 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2019 | 5227 | 0.080 |
Why?
| | Cold Temperature | 2 | 2019 | 130 | 0.080 |
Why?
| | Equipment Design | 2 | 2019 | 517 | 0.080 |
Why?
| | Breast Feeding | 1 | 2010 | 381 | 0.070 |
Why?
| | Weight Gain | 1 | 2010 | 486 | 0.070 |
Why?
| | Incidence | 1 | 2012 | 2413 | 0.070 |
Why?
| | Seasons | 2 | 2019 | 462 | 0.070 |
Why?
| | Mass Screening | 1 | 2012 | 1048 | 0.070 |
Why?
| | Child Abuse | 1 | 2010 | 465 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1434 | 0.060 |
Why?
| | Risk | 2 | 2017 | 845 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2487 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1162 | 0.060 |
Why?
| | Diet | 1 | 2011 | 1143 | 0.060 |
Why?
| | Insulin Resistance | 1 | 2011 | 1167 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2023 | 103 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 63 | 0.050 |
Why?
| | Hospitalization | 2 | 2024 | 1778 | 0.050 |
Why?
| | Reference Standards | 1 | 2021 | 173 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 70 | 0.050 |
Why?
| | Pancreas | 1 | 2022 | 279 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2023 | 551 | 0.050 |
Why?
| | Inpatients | 1 | 2024 | 388 | 0.050 |
Why?
| | Social Conditions | 1 | 2019 | 13 | 0.040 |
Why?
| | Disease Management | 1 | 2023 | 567 | 0.040 |
Why?
| | Equipment and Supplies | 1 | 2018 | 38 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 174 | 0.040 |
Why?
| | Postprandial Period | 1 | 2018 | 96 | 0.040 |
Why?
| | Time Factors | 2 | 2018 | 6362 | 0.040 |
Why?
| | Virginia | 1 | 2017 | 52 | 0.040 |
Why?
| | Mobile Applications | 1 | 2020 | 145 | 0.040 |
Why?
| | Snacks | 1 | 2017 | 17 | 0.040 |
Why?
| | Colorado | 2 | 2017 | 4175 | 0.040 |
Why?
| | Reference Values | 1 | 2018 | 764 | 0.040 |
Why?
| | Accelerometry | 1 | 2017 | 72 | 0.040 |
Why?
| | Ohio | 1 | 2017 | 140 | 0.040 |
Why?
| | Minnesota | 1 | 2017 | 137 | 0.040 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 98 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2017 | 266 | 0.040 |
Why?
| | Hypertrophy | 1 | 2016 | 122 | 0.030 |
Why?
| | Food Preferences | 1 | 2017 | 118 | 0.030 |
Why?
| | Materials Testing | 1 | 2017 | 360 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 213 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 700 | 0.030 |
Why?
| | Pain Measurement | 1 | 2017 | 468 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 594 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2022 | 6533 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1195 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2652 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 5072 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3160 | 0.020 |
Why?
|
|
Forlenza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|